Clinical trials: Reduced Left Ventricular Ejection Fraction
Non-Ischemic Heart Failure, Reduced Ejection Fraction Heart Failure
ASCs in Recently Diagnosed Non-ischemic Heart Failure
The goal of this clinical trial is to investigate the efficacy and safety of intravenous infusions of allogeneic adipose tissue-derived mesechymal stromal cells in patients with recently diagnosed non-ischemic heart failure in…
- Trial name
- ARIISE (NCT06840275)
- Testing
- Allogeneic adipose tissue-derived mesenchymal stem cells, Cryostor CS10
- Where
- Denmark
- Sponsor
- Cell to Cure ApS
Tricuspid Insufficiency, Tricuspid Regurgitation (TR)
PASCAL Precision-GDMT Registry
The goal of this observational study is to demonstrate that successful tricuspid valve repair with the PASCAL Precision System in participants with at least severe tricuspid insufficiency and left ventricular dysfunction will be…
- Conditions
- Tricuspid Insufficiency, Tricuspid Regurgitation (TR), Left Ventricular Cardiac Dysfunction, Left Ventricular (LV) Systolic Dysfunction
- Trial name
- PASCAL (NCT07578129)
- Volunteers
- 50 people
- Sponsor
- Ceric Sàrl
Heart Failure, Heart Failure With Reduced Ejection Fraction
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure…
- Trial name
- COMET-HF (NCT06736574)
- Testing
- Omecamtiv Mecarbil (OM)
- Where
- 209 sites in United States, Canada and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Cytokinetics
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
This was a retrospective observational cohort study using patient data from the Get With The Guideline-Heart Failure (GWTG-HF) registry linked to Medicare Fee-for-Service (FFS) claims.
- Trial name
- NCT06671314
- Where
- United States
- Volunteers
- 42,494 people
- Sponsor
- Novartis
Heart Failure Low Output, Heart Failure
The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients
This study aims to investigate safety and efficacy of the Occlutech® AFR device in patients with HFrEF (Heart failure with reduced ejection fraction) and HFpEF (Heart failure with preserved ejection fraction)
- Trial name
- PRELIEVE (NCT03030274)
- Testing
- Occlutech AFR device
- Where
- 26 sites in Belgium, Germany and 1 more
- Volunteers
- 106 people
- Sponsor
- Occlutech International AB
Heart Failure, Heart Failure, Systolic
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and…
- Conditions
- Heart Failure, Heart Failure, Systolic, Erectile Dysfunction
- Trial name
- CONFIDENCE-HF (NCT03917459)
- Testing
- LCZ696, Enalapril
- Where
- 13 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of…
- Trial name
- NCT04630067
- Testing
- AZD3427
- Where
- 10 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure and Reduced Ejection Fraction, NYHA Class III Heart Failure
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
The purpose of this prospective, multi-center, propensity-matched coverage with evidence development (CED) study is to assess the impact of cardiac contractility modulation (CCM) on mortality and heart failure hospitalizations in…
- Trial name
- BRIGHTEN-HF (NCT07209098)
- Testing
- Cardiac Contractility Modulation (CCM)
- Where
- United States
- Volunteers
- 4,200 people
- Sponsor
- Impulse Dynamics
Myocardial Infarction
A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction
The purpose of the trial is the analysis of safety and efficacy of the chymase inhibitor BAY1142524 at a dose of 25 mg BID in comparison to placebo using a 6 months treatment period in patients with left-ventricular (LV)…
- Trial name
- CHIARA MIA 2 (NCT02976467)
- Testing
- Fulacimstat (BAY1142524)
- Where
- 25 sites in Czechia, Germany and 3 more
- Volunteers
- 107 people
- Sponsor
- Bayer
Heart Failure, Heart Failure NYHA Class III
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
The purpose of this early feasibility study is to evaluate the safety and feasibility of the device for percutaneous shunting of the interatrial septum and improvement of heart failure related symptoms.
- Conditions
- Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
- Trial name
- EASE HF2 (NCT06859970)
- Testing
- PAS-C System
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- InterShunt Technologies, Inc.
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
- Trial name
- NCT06632483
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- India
- Volunteers
- 604 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
The aim of this study was to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine…
- Trial name
- REACT-HFrEF-RO (NCT07465679)
- Where
- Romania
- Volunteers
- 2,508 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Preserved Ejection Fraction
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition…
- Trial name
- DELIVER (NCT03619213)
- Testing
- Dapagliflozin
- Where
- 348 sites in United States, Argentina and 18 more
- Volunteers
- 6,263 people
- Sponsor
- AstraZeneca
Heart Failure, Acute Decompensated Heart Failure
Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance
Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance
- Conditions
- Heart Failure, Acute Decompensated Heart Failure, Cardiorenal Syndrome, Heart Failure, Congestive
- Trial name
- NCT06174623
- Testing
- ModulHeart Support
- Where
- 5 sites in Australia, Georgia
- Volunteers
- 5 people
- Sponsor
- Puzzle Medical Devices Inc.
Heart Failure and Reduced Ejection Fraction
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection…
- Trial name
- EVALUATE-HF (NCT02874794)
- Testing
- LCZ696 (sacubitril/valsartan), Enalapril
- Where
- 81 sites in United States
- Volunteers
- 465 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction…
- Trial name
- NCT04331769
- Testing
- AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
- Where
- 122 sites in United States, Belarus and 8 more
- Volunteers
- 400 people
- Sponsor
- Ancora Heart, Inc.